Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e-Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

FDA Oncology Update

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Online Only

FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality

Online Only

Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Page 1 of 20
Results 1 - 10 of 191